Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Zevra Therapeutics

Zevra Therapeutics (NASDAQ: ZVRA) insider transactions

In the twelve months to 10 November 2026, executives and directors of Zevra Therapeutics reported 13 open-market sales of 244,180 shares ($2.5m) and 0 open-market purchases, by 6 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Zevra Therapeutics shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
12 October 2026McFarlane Neil F.President and CEOOpen-market sale, 10b5-1 plan−20,000$11.25417,225Form 4
10 October 2026McFarlane Neil F.President and CEOOption exercise, 10b5-1 plan+50,000—437,225Form 4
14 August 2026Thompson RahsaanChief Legal & ComplianceOpen-market sale, 10b5-1 plan−42,666$11.1337,569Form 4
10 August 2026Watton Corey MichaelDirectorOption exercise+12,300$4.9714,100Form 4
10 August 2026Watton Corey MichaelDirectorOpen-market sale−12,300$11.251,800Form 4
22 June 2026Thompson RahsaanChief Legal & ComplianceOpen-market sale, 10b5-1 plan−34,557$12.6880,235Form 4
21 June 2026Thompson RahsaanChief Legal & ComplianceOption exercise, 10b5-1 plan+66,667—114,792Form 4
11 May 2026Thompson RahsaanChief Legal & ComplianceOpen-market sale, 10b5-1 plan−1,794$11.3048,125Form 4
24 March 2026Bode John BDirectorOption exercise+39,200$4.9784,200Form 4
24 March 2026Bode John BDirectorOption exercise+39,200$4.89123,400Form 4
9 February 2026McFarlane Neil F.President and CEOOpen-market sale, 10b5-1 plan−14,625$8.56387,225Form 4
7 February 2026McFarlane Neil F.President and CEOOption exercise, 10b5-1 plan+37,500—401,850Form 4
3 February 2026Sangiovanni Timothy J.SVP, Finance & Corp ControllerOpen-market sale, 10b5-1 plan−3,000$9.1829,590Form 4
3 February 2026Schafer JoshuaCcoOpen-market sale, 10b5-1 plan−10,500$9.1962,278Form 4
2 February 2026McFarlane Neil F.President and CEOOpen-market sale, 10b5-1 plan−91,000$9.38364,350Form 4
31 January 2026McFarlane Neil F.President and CEOOption exercise, 10b5-1 plan+233,334—455,350Form 4
31 January 2026Sangiovanni Timothy J.SVP, Finance & Corp ControllerOption exercise, 10b5-1 plan+11,666—32,590Form 4
31 January 2026Schafer JoshuaCcoOption exercise, 10b5-1 plan+35,334—72,778Form 4
30 January 2026Sangiovanni Timothy J.SVP, Finance & Corp ControllerOption exercise, 10b5-1 plan+6,333—22,674Form 4
30 January 2026Sangiovanni Timothy J.SVP, Finance & Corp ControllerOpen-market sale, 10b5-1 plan−1,750$8.8220,924Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Zevra Therapeutics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.